Tag Archives: Protalix

October, 2015

  • 13 October

    Protalix Sells its Share of its Gaucher Drug to Pfizer for $46 Million

    CARMIEL, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company sold its share in the collaboration agreement for ELELYSOTM to its commercialization partner, Pfizer Inc. Under the initial collaboration agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of ELELYSO on a 60%/40% …